TrialAlzheimer's research & therapy2026

Etalanetug (E2814) in dominantly inherited Alzheimer's disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairment.

Erica Andreozzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.